Teleflex (NYSE:TFX) Rating Lowered to Sell at Wall Street Zen

Teleflex (NYSE:TFX) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday. A number of other analysts have also recently weighed in on TFX. Raymond James Financial reaffirmed an "outperform" rating and set a $150.00 price objective on shares of Teleflex in a research report on Friday. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Teleflex in a research report on Friday, March 27th. Royal Bank Of Canada raised Teleflex from a "sector perform" rating to an "outperform" rating and increased their price objective for the stock from $135.00 to $155.00 in a research report on Friday. Mizuho set a $140.00 price objective on Teleflex in a research report on Friday. Finally, Bank of America raised Teleflex from an "underperform" rating to a "neutral" rating and set a $135.00 price objective for the company in a research report on Monday, April 13th. Three investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Teleflex currently has an average rating of "Hold" and an average target price of $142.86. Teleflex stock opened at $133.17 on Friday. Teleflex has a twelve month low of $100.18 and a twelve month high of $139.67. The stock has a 50 day moving average of $119.44 and a two-hundred day moving average of $116.73. The company has a current ratio of 2.55, a quick ratio of 2.01 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $5.89 billion, a price-to-earnings ratio of -5.84, a PEG ratio of 0.95 and a beta of 0.82. Teleflex last posted its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts' consensus estimates of $1.21 by $0.18. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%. The company had revenue of $548.30 million during the quarter, compared to analysts' expectations of $536.91 million. During the same period last year, the firm earned $1.44 EPS. The firm's revenue for the quarter was up 32.3% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, research analysts expect that Teleflex will post 6.75 earnings per share for the current year. A number of large investors have recently modified their holdings of the business. Janus Henderson Group PLC raised its stake in shares of Teleflex by 2.0% during the 4th quarter. Janus Henderson Group PLC now owns 4,246,112 shares of the medical technology company's stock worth $518,196,000 after buying an additional 84,754 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Teleflex by 478.1% during the 3rd quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company's stock worth $287,603,000 after buying an additional 1,956,811 shares in the last quarter. State Street Corp raised its stake in shares of Teleflex by 1.5% during the 4th quarter. State Street Corp now owns 1,478,776 shares of the medical technology company's stock worth $180,470,000 after buying an additional 22,111 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Teleflex by 0.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company's stock worth $152,630,000 after buying an additional 5,051 shares in the last quarter. Finally, Cooke & Bieler LP raised its stake in shares of Teleflex by 1.2% during the 3rd quarter. Cooke & Bieler LP now owns 1,220,637 shares of the medical technology company's stock worth $149,357,000 after buying an additional 14,673 shares in the quarter. 95.62% of the stock is owned by hedge funds and other institutional investors. Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes. The company's offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.